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Abstract
Background: In the healthcare sector, it is crucial to identify sustainable strategies in order to allow the
introduction and use of innovative technologies. Now, and over the next few years, the expiry of patents for
different antiretroviral drugs offers an opportunity to increase the efficiency of resources allocation. The aim of the
present study was to assess the impact, on the budget of the Italian National Healthcare Service, of generic
antiretroviral drugs and of new antiretroviral drugs entering the market from 2015 to 2019.
Methods: A budget impact model was developed in order to forecast the rate of use of ARTs, based on trends
observed within the Lombardy Region (Italy), on clinical experts’ opinion, and the consequent impact on the Italian
NHS budget in a five year time horizon. Different scenarios were developed, considering the sole introduction of
generic drugs, of new drugs, and their cumulative effects. A multivariate sensitivity analysis was also performed.
Results: The cumulative use of generic drugs and new drugs would lead to annual savings of 4.6 million € (-0.6 %)
in 2015; 16.9 million € (-2.1 %) in 2016; 19.4 million € (-2.4 %) in 2017; 51.1 million € (-6.1 %) in 2018 and -110.3
million € (-12.8 %) in 2019. The impact of new drugs in percentage terms is +2.0 % in 2015, +3.4 % in 2016, +3.9 %
in 2017, +5.7 % in 2018 and +7.7 % in 2019. The impact of generic drugs would lead to savings of 4.9 million € in
2015, 18.6 million € in 2016, 22.8 million € in 2017, 76.5 million € in 2018 and 187.4 million € in 2019.
The sensitivity analysis showed annual mean savings for the Italian NHS ranging from 12.6 million €, -1.5 %
compared to the base case scenario (decreasing all the rates of transition used in the simulation, and increasing the
cost of generic drugs) to 76.0 million €, -9.1 % (increasing all the rates of transition used in the simulation, and
decreasing the cost of generic and new drugs).
Conclusions: The use of antiretroviral generic drugs may lead to savings that would compensate the expenditure
increase due to new, innovative drugs available on the market.
Background
Since 2005, the availability of new antiretroviral drugs
which offer high efficacy and acceptability and less
toxicity, has led to a decrease of HIV related deaths
worldwide [1, 2], compared with the pre Highly Active
Antiretroviral Therapy (HAART) era. As a result of
advances in treatment, HIV infection is now considered
as a chronic disease [3]: patients have to follow
Antiretroviral Therapies (ARTs) for several years, thus
increasing the relevance of compliance, and exposing
them to long-term adverse events.
Although progress has been substantial, uncertainties
persist concerning the best way to manage HIV disease [4].
Health-care decision making and management of
medical technologies and drugs is crucial in the health-
care sector, since innovative technologies often lead to
an increase of costs [5–7]. This is the case with
antiretroviral drugs, which are often more effective and
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more expensive (although in some cases the increased
cost of drugs is compensated by a reduction of adverse
events and, therefore of inpatient and outpatient activities
for healthcare services). Sullivan and colleagues [8] showed
how HIV, in terms of cost per person, was the third most
expensive disease in France in 2005, with a cost per person
of 11,900 €, above the 7,000 € mean expense for all dis-
eases. In Italy, Magoni and colleagues [9] analysed the per
capita cost in 2007 for the Healthcare Service of Lombardy
Region of patients referring to a Local Health Authority
with more than 1.1 million inhabitants. HIV infection was
found to be the third most expensive chronic disease,
considering direct medical costs (inpatient, outpatient activ-
ities and drugs) and the most expensive considering drugs
alone.
Two further Italian studies conducted within the 1st
and 2nd Infectious Diseases wards at Luigi Sacco Hospital,
based in Milan, among 653 and 483 patients respectively,
showed a constant yearly increase in the mean HAART
costs in periods 2004 − 2007 and 2007 − 2009 [10, 11].
In such a scenario, the current economic recession has
led some European and North American governments to
adopt austerity policies, during a period in which counter-
cyclical investments would be needed [12, 13] and concerns
over the sustainability of health care expenditures have
been raised.
To face this challenging situation an increase in the effi-
ciency of resources allocation is needed, identifying cost
saving strategies that ensure the efficacy of treatments.
Different approaches have been used among European
countries, shifting expensive drugs to second line treat-
ments, as within the French guidelines for antiretroviral
treatments [14], shifting patients to less drugs regimen,
encouraging cost-effectiveness criteria and promoting the
use of generic drugs. Considering this strategy, over the
next few years different patents for antiretroviral drugs will
expire, thus allowing generic drugs to enter the market,
with the positive effects of lowering the cost of treatments.
The aim of the present study was to assess the impact on
budget of the Italian National Healthcare Service (INHS) of
new generic antiretroviral drugs and of new antiretroviral
drugs entering the market between 2015 and 2019. The
budget impact of these two categories of antiretroviral
treatments was investigated (both separately and in a
cumulative way), in order to inquire if the savings due to
the use of generic drugs could balance the increased cost of
antiretroviral treatment resulting from the use of the new
antiretroviral drugs.
Methods
In order to assess the potential impact of generic drugs
and new antiretroviral drugs on the budget of the INHS, a
model was developed to forecast the rate of use of ARTs.
The trends in the rate of consumption of HIV antiretro-
viral drugs observed by the Lombardy Region HIV/AIDS
group of technical experts between 2010 and 2012 were
considered to forecast the use of ARTs in a five year time
horizon, [15] from 2015 to 2019, based on clinical experts
opinion. Input from experts were based on the direct
clinical experience of clinicians referring to the Infectious
Disease Department of two Hospital Authorities within the
previously mentioned region.
The model structure considers cycles of six months. In
order to forecast the use of each ART, the rate of con-
sumption estimated in each semester was multiplied by
the number of HIV infected subjects on ART, calculated
considering the data provided by the Italian National
Institute of Health [16].
A base case scenario was created, estimating the trends
of consumption of the brand and generic antiretroviral
drugs already being used in 2015. A comparative scenario
was developed estimating the consumption of ART follow-
ing the introduction of new brand drugs and of generic
drugs: DTG, ABC/3TC/DTG, TAF/FTC/EVG/COBI, TAF/
FTC/RPV, TAF/FTC, generic ABC, generic LPV, generic
NVP, generic TDF/FTC/EFV, generic DRV, generic ATV.
The estimated effects of each new drug on the rate of con-
sumption of other drugs are reported in Table 1.
Regional clinical pathways in Italy suggest the use of
single tablet regimens, where possible. Therefore, in the
definition of the therapy switch strategies, the availability
of multiple generic pills had a limited effect on the rate
of use of co-formulated tablet, to preserve the compli-
ance of the patients.
The analysis was also performed considering the impact
of the two categories of new therapies (new drugs and
generic drugs) alone. The semester in which each generic
drug entered the model was the same as that of the expir-
ation date of the drug complementary protection certificate.
In year 1 (2015) patients were allocated within the therapies
considered in the model, as estimated through the rate of
drugs consumption observed. The “other therapies” cat-
egory included all the patients not receiving any of the ther-
apies considered in the model (Additional file 1).
The cost considered was that of the antiretroviral drugs,
referred to 2015 levels, as reported in the HIV/AIDS
Clinical Pathway of the Lombardy Region [17] and was
undiscounted [15] (presented in Table 2). The cost per
patient per semester was calculated by multiplying the
monthly therapy cost by 5.25, due to the fact that the repro-
cessing of the data within the Lombardy Region HIV/AIDS
group of technical experts showed (due to a lack of
complete compliance) a per patient yearly mean consump-
tion of HIVART daily doses of 10.5 months.
The generic drugs cost was estimated to be 40 % of
the branded cost. The three generic antiretroviral drugs
available in 2015 in Italy, lead in Lombardy Region to a
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Table 1 The model’s base case hypotheses – effects of generic and new drugs
Drug Semester in which it
enters in the model
Effects [sensitivity analysis rates]
Generic ABC First semester 2015 100 % of patients receiving branded ABC switch to generic ABC in the semester in which the
new drug enter the model [85 %; 100 %]
10 % of patients receiving ABC/3TC switch to generic 3TC + generic ABC in the semester in
which the new drug enter the model [5 %; 25 %]
Generic LPV First semester 2016 100 % of patients receiving branded LPV switch to generic LPV in the semester in which the
new drug enter the model [85 %; 100 %]
Generic NVP 400 Second semester 2016 100 % of patients receiving branded NVP switch to generic NVP in the semester in which the
new drug enter the model [85 %; 100 %]
Generic TDF/FTC/EFV Second semester 2018 60 % of patients receiving branded TDF/FTC/EFV switch to generic TDF/FTC/EFV [50 %; 100 %]
35 % of patients receiving branded TDF/FTC/EFV should switch to generic TDF/FTC/EFV, however
clinicians prefer a switch to TAF/FTC/RPV following indications of clinical pathway [25 %; 0 %]
5 % of patients receiving branded TDF/FTC/EFV should switch to generic TDF/FTC/EFV, however
clinicians prefer a switch to TAF/FTC/EVG/COBI following indications of clinical pathway [0 %; 0 %]
Generic DRV Second semester 2018 50 % of patients receiving branded DRV + TDF/FTC switch to generic DRV + TAF/FTC [40 %; 100 %]
15 % of patients receiving branded DRV + TDF/FTC should switch to generic DRV + TAF/FTC, however
clinicians prefer a switch to TAF/FTC/EVG/COBI following indications of clinical pathway [5 %; 0 %]
15 % of patients receiving branded DRV + TDF/FTC should switch to generic DRV + TAF/FTC, however
clinicians prefer a switch to TAF/FTC + DTG following indications of clinical pathway [5 %; 0 %]
20 % of patients receiving branded DRV + TDF/FTC should switch to generic DRV + TAF/FTC, however
clinicians prefer a switch to TAF/FTC/RPV following indications of clinical pathway [10 %; 0 %]
DRV + ABC/3TC switch to generic DRV + ABC/3TC [40 %; 100 %]
50 % of patients receiving branded DRV + ABC/3TC should switch to generic DRV + ABC/3TC, however
clinicians prefer a switch to ABC/3TC/DTG following indications of clinical pathway [40 %; 0 %]
Generic ATV First semester 2019 50 % of patients receiving branded ATV + TAF/FTC switch to generic ATV + TAF/FTC[40 %; 100 %]
15 % of patients receiving branded ATV + TDF/FTC should switch to generic ATV + TAF/FTC, however
clinicians prefer a switch to TAF/FTC/EVG/COBI following indications of clinical pathway [5 %; 0 %]
15 % of patients receiving branded ATV + TDF/FTC should switch to generic ATV + TAF/FTC, however
clinicians prefer a switch to TAF/FTC + DTG following indications of clinical pathway [5 %; 0 %]
20 % of patients receiving branded ATV + TDF/FTC should switch to generic ATV + TAF/FTC, however
clinicians prefer a switch to TAF/FTC/RPV following indications of clinical pathway [10 %; 0 %]
50 % of patients receiving branded ATV + ABC/3TC switch to generic ATV + ABC/3TC [40 %; 100 %]
50 % of patients receiving branded ATV + ABC/3TC should switch to generic ATV + ABC/3TC, however
clinicians prefer a switch to ABC/3TC/DTG following indications of clinical pathway [40 %; 0 %]
DTG First semester 2015 10 % of switching patients receiving DRV (0.78 %) switch to DTG in each semester [5 %; 25 %]
10 % of switching patients receiving ATV (0.78 %) switch to DTG in each semester [5 %; 25 %]
75 % of switching patients receiving RAL (5.87 %) switch to DTG in each semester [50 %; 75 %]
ABC/3TC/DTG Second semester 2015 100 % of patients receiving ABC/3TC + DTG switch to ABC/3TC/DTG in the semester in which
the new drug enter the model [85 %; 100 %]
20 % of patients receiving TDF/FTC + DTG switch to ABC/3TC/DTG in the semester in which the
new drug enter the model [10 %; 30 %]
TAF/FTC/EVG/COBI Second semester 2016 100 % of patients receiving TDF/FTC/EVG/COBI switch to TAF/FTC/EVG/COBI in the semester in
which the new drug enter the model [100 %; 100 %]
TAF/FTC First semester 2017 100 % of patients receiving TDF/FTC switch to TAF/FTC in the semester in which the new drug
enter the model [100 %; 100 %]
TAF/FTC/RPV Second semester 2017 100 % of patients receiving TDF/FTC/RPV switch to TAF/FTC/RPV in the semester in which the
new drug enter the model [100 %; 100 %]
Abbreviations: 3TC Lamivudine, EFV Efavirenz, TDF Tenofovir Disoproxil Fumarate, FTC Emtricitabine, NVP Nevirapine, ABC Abacavir, LPV Lopinavir, DTG
Dolutegravir, DRV Darunavir, RAL Raltegravir, EVG Elvitegravir, COBI Cobicistat, RPV Rilpivirine, TAF Tenofovir Alafenamide Fumarate. Table legend text
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mean reduction compared to the branded drugs price of
63.0 %, as observed within HIV/AIDS clinical pathways
[17–19], therefore we approximate to 60 % the cost
reduction. The cost of new drugs were considered at the
same level of their main competitor or adding the cost
of each active ingredient. The cost per patient of “other
therapies” was calculated by subtracting the cost of the
ART considered in the model from the INHS ART
expenditures [20]. The result was divided by the number
of patients within this category.
A sensitivity analysis was also conducted in order to
assess the robustness of the results. The parameters
changed were the price of generic drugs (20 % of brand
drugs price; and 60 % of brand drug price), the price of
new drugs (-10 % than the base case scenario price) and
the rate of use of generic drugs and of new drugs, as
reported in Table 1.
An increase in the number of HIV positive patients
treated with ART was estimated in the analysis (based
on data on new diagnosis provided by the Italian
National Health Institute) [21], being 94,727 in the
second semester of 2015, 99,205 in the second semester
of 2016, 103,893 in the second semester of 2017,
108,804 in the second semester of 2018 and 113,946 in
the second semester of 2019.
Results
The consumption of generic drugs increased each semester,
starting from a number of patients receiving at least one
generic drug equal to 12,846 in the second semester of
2015, to 16,035 in the second semester of 2016, to 16,851
in the second semester of 2017, to 34,946 in the second
semester of 2018 and to 50,866 in the second semester of
2019. In the last semester of the analysis, the number of
Table 2 Drugs prices considered in the analysis as reported within the HIV/AIDS Clinical Pathway of the Lombardy Region
Drug Daily dose Brand drug monthly cost (€) Generic drug monthly cost (€) Source for brand price
ABC 300 mg 2 224.40 89.76 [17]
ATV 200 mg 2 503.58 201.43 [17]
ATV 300 mg 1 332.97 133.19 [17]
DRV 400 mg 2 348.48 139.39 [17]
DRV 600 mg 2 528.00 211.20 [17]
DTG 50 mg 1 495.15 - [17]
EFV 600 mg 1 128.68 128.68 [17]
FTC 200 mg 1 161.37 64.55 [17]
3TC 300 mg or 150 mg 1 (300 mg) or
2 (150 mg)
25.74 25.74 [17]
NVP 400 mg 1 178.53 71.41 [17]
RAL 400 mg 2 438.90 - [17]
RPV 25 mg 1 230.67 - [17]
Ritonavir 100 mg 1 or 2 24.97 (100 mg) - [17]
TDF 245 mg 1 276.87 - [17]
TAF 245 mg 1 276.87 - Expert opinion
TDF/FTC 200/245 mg 1 438.90 - [17]
TAF/FTC 200/245 mg 1 438.90 - Expert opinion
ABC/3TC 600/300 mg 1 398.31 - [17]
3TC/AZT 150/300 mg 2 66.00 66.00 [17]
LPV/r 200/50 mg 4 357.72 143.09 [17]
ABC/3TC/AZT 300/150/300 mg 2 500.28 - [17]
ABC/3TC/DTG 600/300/50 mg 1 893.46 - Expert opinion
FTC/TDF/EFV 200/245/600 mg 1 596.70 238.68 [17]
FTC/TDF/RPV 200/245/25 mg 1 598.62 - [17]
FTC/TAF/RPV 200/245/25 mg 1 598.62 - Expert opinion
EVG/COBI/FTC/TDF 150/150/200/245 mg 1 797.61 - [17]
EVG/COBI/FTC/TAF 150/150/200/245 mg 1 797.61 - Expert opinion
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patients receiving at least one generic drug represents
44.6 % of the number of HIV positive patients receiving
ART.
The yearly cost of ART to treat the whole population of
HIV positive patients for the INHS in the two scenarios
(without new and generic drugs, and with new and generic
drugs), the cost per capita and the yearly percentage
differences are reported in Table 3.
The percentage savings for the INHS are -0.6 % in
2015, -2.1 % in 2016, -2.4 % in 2017, -6.1 % in 2018
and -12.8 % in 2019, corresponding respectively to 4.6
million €, 16.9 million €, 19.4 million €, 51.1 million € and
110.3 million €.
Considering the per capita yearly ART cost, the scenario
that does not consider new and generic drugs shows a
linear cost decrease from 8,0975 € in year 2015 to 7.575 €
in 2019. The per capita ART cost in the scenario that
considers new and generic drugs led to a yearly cost
decrease (compared with the previous year) of, -3.0 % in
2016, -1.8 % in 2017, -5.4 % 2018 and -8.7 in 2019.
Further analyses were performed, isolating the effects
of new antiretroviral drugs and of generic drugs on the
INHS budget. Considering the previously mentioned cat-
egories alone, the differential costs, compared with the
base case scenario are reported in Table 4.
The impact of new drugs in percentage terms was +2.0 %
in 2015, +3.4 % in 2016, +3.9 in 2017, +5.7 % in 2018
and +7.7 % in 2019.
Different results were obtained considering generic
drugs only. The impact of these technologies on the
INHS budget would lead to savings in years 2015 − 2019
of -5.0 million € in 2015, -18.6 million € in 2016, -22.8
million € in 2017, 76.5 million € in 2018 and -187.4
million € in 2019.
The yearly total cost of each scenario is presented in
Fig. 1.
The sensitivity analysis results, showed annual mean sav-
ings for the INHS ranging from 12.6 million €, -1.5 % com-
pared to the base case scenario (decreasing all the rates of
transition used in the simulation, and increasing the cost
of generic drugs) to 76.0 million €, -9.1 % (increasing all
the rates of transition used in the simulation, and decreas-
ing the cost of generic and new drugs) (Table 5).
Discussion
The actual context of resources constraints has forced
national health services to design strategies in order to
increase the efficiency of resources allocation and treat-
ment appropriateness. Among the possible strategies to
contain costs for the management of HIV positive
patients, without affecting the efficacy of therapies, the
use of generic drugs is one of the most feasible, since it
does not affect the patient pathway in terms of increased
outpatients activities. Due to the increase in patient’s
survival years, a new paradigm for the management of HIV
positive patients has been established. The use of effective
Table 4 The model’s results considering the effect of new and generic drugs alone
2015 2016 2017 2018 2019
Number of patients 94,727 99,205 103,893 108,804 113,946
New antiretroviral drugs scenario Total ART cost (€) 780,148,483 815,891,938 845,063,294 885,581,470 929,655,763
Per capita ART cost (€) 8,236 8,224 8,134 8,139 8,159
Δ in total cost (€) compared to base case +15,186,448 +26,880,786 +31,666,260 +47,465,974 +66,496,550
% Δ in total cost +2.0 % +3.4 % +3.9 % +5.7 % +7.7 %
Generic drugs scenario Total ART cost (€) 759,981,491 770,436,043 790,580,416 761,583,789 675,775,852
Per capita ART cost (€) 8,023 7,766 7,610 7,000 5,931
Δ in total cost (€) −4,980,545 −18,575,109 −22,816,617 −76,531,708 −187,383,361
% Δ in total cost −0.7 % −2.4 % −2.8 % −9.1 % −21.7 %
Table 3 The model’s results considering the cumulative effect of new and generic drugs
2015 2016 2017 2018 2019
Number of patients 94,727 99,205 103,893 108,804 113,946
No new and generic drugs scenario Total ART cost (€) 764,962,036 789,011,152 813,397,033 838,115,496 863,159,214
Per capita ART cost (€) 8,075 7,953 7,829 7,703 7,575
New and generic drugs scenario Total ART cost (€) 760,408,704 772,152,627 794,021,079 787,013,681 752,848,759
Per capita ART cost (€) 8,027 7,783 7,643 7,233 6,607
Δ in total cost (€) −4,553,331 −16,858,525 −19,375,954 −51,101,815 −110,310,454
% Δ in total cost −0.6 % −2.1 % −2.4 % −6.1 % −12.78 %
Restelli et al. BMC Infectious Diseases  (2015) 15:323 Page 5 of 7
therapies with high genetic barrier increase the future
therapeutic options for patients and are, therefore, to be
considered as first line therapies. However, new drugs with
the aforementioned characteristics have high costs, com-
pared to the therapies already available on the market.
The present study shows how the savings due to cost
containing strategies (such as the use of generic drugs)
would allow investment in more expensive drugs, with
possible future savings related to the increased range of
therapies to be administered once the first ART leads to
a virological failure.
The results show savings related to the use of generic
drugs, in the same range of previously published data
related to the Italian context [22] (for Lazio Region), while
data published concerning the U.K. [23], estimate further
savings, around 20 % in years 2014, 2015 and 2016, and
around 70 % in years 2017 and 2018 (even though the price
reduction of generic drugs, in the study presented by Hill
and colleagues, is higher than the hypothesis made in the
present study, and the years considered in the two studies
are different).
Finally, although the findings suggest that the use of
generic drugs could generate significant cost savings,
there were limitations with the present study. The ana-
lysis performed focused on ART costs and did not con-
sider hospitalizations, outpatient activities and other
drugs, and the likely fewer activities due to the use of
new drugs, leading to further savings.
The conservative assumptions of the model were also
related to the fact that the analysis was based on a com-
parative scenario taken from the Lombardy Region, that
has been able to control, over the past years, the per
capita costs of HIV positive patients through the imple-
mentation of a clinical pathway. Therefore, comparing
the results of the analysis with such an efficient scenario,
may have underestimated the advantages at a National
level.
Conclusions
In conclusion, the use of generic antiretroviral drugs
within the INHS may lead to savings, compensating
for any expenditure increase due to the use of new,
Fig. 1 Total cost of the 4 scenarios and sensitivity analysis range of the “new and generic antiretroviral drugs” scenario
Table 5 Sensitivity analysis results: percentage difference between “New and generic drugs scenarios”, and the scenario that does
not consider new and generic drugs
Scenario 2015 2016 2017 2018 2019 5 Years mean difference
Base case −0.6 % −2.1 % −2.4 % −6.1 % −12.8 % −4.8 %
Increased costs −0.5 % −1.4 % −1.3 % −3.9 % −8.4 % −3.1 %
Decreased costs −0.7 % −3.0 % −3.6 % −9.1 % −19.0 % −7.1 %
Increased switch rates −2.3 % −3.9 % −4.2 % −7.7 % −14.6 % −6.6 %
Decreased switch rates 0.2 % −0.7 % −0.9 % −4.0 % −9.6 % −3.0 %
Increased costs and decreased switch rates 0.2 % −0.1 % 0.0 % −1.9 % −5.5 % −1.5 %
Increased costs and switch rates −2.1 % −3.0 % −3.0 % −5.3 % −9.7 % −4.6 %
Decreased costs and switch rates 0.2 % −1.2 % −1.6 % −6.2 % −14.4 % −4.7 %
Decreased costs and increased switch rates −2.9 % −5.3 % −5.9 % −10.9 % −20.7 % −9.1 %
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innovative drugs available on the market. The identifi-
cation of cost containing strategies, such as the one
presented in the present study, would thus allow the
sustainability of the use of new drugs at a time of in-
creased budget constraints.
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